Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer Namrata VijayvergiaRanee Mehra Review Article 19 August 2014 Pages: 437 - 446
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer Keun-Wook LeeYu Jung KimJee Hyun Kim Original Article 20 June 2014 Pages: 447 - 455
Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®) Marye J. Boers-SonderenCarla M. L. van HerpenNielka P. van Erp Original Article 26 June 2014 Pages: 457 - 463
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors Matthew D. GalskyMarshall PosnerWilliam K. Oh Original Article 15 July 2014 Pages: 465 - 471
Studies on assessment methods of malignant ascites residue and changes of verapamil concentration in intraperitoneal perfusion chemotherapy Chengtao WenQiaohong DuanWeidong Jia Original Article 16 July 2014 Pages: 473 - 478
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan Caio Max Rocha-LimaEriberto de Queiroz Marques JuniorShabbir Susnerwala Original Article 17 July 2014 Pages: 479 - 486
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma Yun ZhengSigal GeryH. Phillip Koeffler Original Article 17 July 2014 Pages: 487 - 495
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer Takaya IkedaMinoru FukudaNagasaki Thoracic Oncology Group Original Article 18 July 2014 Pages: 497 - 502
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study Yulong ZhengWeijia FangNong Xu Original Article 20 July 2014 Pages: 503 - 509
Inhibition of Hec1 as a novel approach for treatment of primary liver cancer Lynn YL HuangChia-chi ChangJohnson YN Lau Original Article 20 July 2014 Pages: 511 - 520
Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer Moon Ki ChoiYeon Hee ParkYoung-Hyuck Im Original Article 22 July 2014 Pages: 521 - 529
RETRACTED ARTICLE: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level Anjing GongNa GeHui Liang Original Article 22 July 2014 Pages: 531 - 538
No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion Toshikado KanetaKen-ichi FujitaYasutsuna Sasaki Original Article 23 July 2014 Pages: 539 - 547
Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide Hans von StedingkHanjing XiePer Rydberg Original Article Open access 23 July 2014 Pages: 549 - 558
Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice Memy H. HassanHesham A. El-BeshbishyMohamed M. Ghobara Original Article 23 July 2014 Pages: 559 - 569
Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia Quentin Chalret du RieuMélanie White-KoningGwenaël Ferron Original Article 23 July 2014 Pages: 571 - 582
A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors Nael M. MostafaYi-Lin ChiuVincent L. Giranda Original Article 23 July 2014 Pages: 583 - 591
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia Aksana KaeferJianning YangHao Xiong Original Article 23 July 2014 Pages: 593 - 602
Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404 Tadahiko ShienHiroji IwataHaruhiko Fukuda Original Article Open access 24 July 2014 Pages: 603 - 609
Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi’s sarcoma (KS) M. BendleJ. PealingM. Bower Original Article 24 July 2014 Pages: 611 - 615
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model Joanne M. BowenBronwen J. MayoDorothy M. K. Keefe Original Article 24 July 2014 Pages: 617 - 627
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors Toshihiko DoiYusuke OnozawaAtsushi Ohtsu Clinical Trial Report Open access 25 July 2014 Pages: 629 - 636
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy Jianliang YangYuankai ShiShuxiang Zhang Clinical Trial Report 18 July 2014 Pages: 637 - 646
Metronomics chemotherapy: time for computational decision support Dominique BarbolosiJoseph CiccoliniFabrice Barlesi Short Communication 01 August 2014 Pages: 647 - 652
Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients Youngil KohSo Young LeeHyang Sook Kim Short Communication 06 August 2014 Pages: 653 - 657
Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers Nianhang ChenDaniel WeissMaria Palmisano Erratum 01 August 2014 Pages: 659 - 660
